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Cross-disease analysis of 
Alzheimer’s disease and type-2 
Diabetes highlights the role of 
autophagy in the pathophysiology 
of two highly comorbid diseases
Laura Caberlotto1,8, T.-Phuong Nguyen  1,2,9, Mario Lauria  1,3, Corrado priami1, 
Roberto Rimondini4, Silvia Maioli5, Angel Cedazo-Minguez  5, Giulia sita6, Fabiana Morroni6, 
Mauro Corsi7 & Lucia Carboni6
Evidence is accumulating that the main chronic diseases of aging Alzheimer’s disease (AD) and 
type-2 diabetes mellitus (T2DM) share common pathophysiological mechanisms. This study aimed at 
applying systems biology approaches to increase the knowledge of the shared molecular pathways 
underpinnings of AD and T2DM. We analysed transcriptomic data of post-mortem AD and T2DM 
human brains to obtain disease signatures of AD and T2DM and combined them with protein-protein 
interaction information to construct two disease-specific networks. The overlapping AD/T2DM network 
proteins were then used to extract the most representative Gene Ontology biological process terms. 
The expression of genes identified as relevant was studied in two AD models, 3xTg-AD and ApoE3/
ApoE4 targeted replacement mice. The present transcriptomic data analysis revealed a principal role 
for autophagy in the molecular basis of both AD and T2DM. Our experimental validation in mouse AD 
models confirmed the role of autophagy-related genes. Among modulated genes, Cyclin-Dependent 
Kinase Inhibitor 1B, Autophagy Related 16-Like 2, and insulin were highlighted. In conclusion, the 
present investigation revealed autophagy as the central dys-regulated pathway in highly co-morbid 
diseases such as AD and T2DM allowing the identification of specific genes potentially involved in 
disease pathophysiology which could become novel targets for therapeutic intervention.
Alzheimer’s disease (AD) is the most common cause of dementia and it is characterized by histopathological, 
molecular, and biochemical abnormalities, including cell loss; abundant neurofibrillary tangles; dystrophic neu-
rites; amyloid-β (APP-Aβ) deposits; impaired energy metabolism; mitochondrial dysfunction; chronic oxidative 
stress; and DNA damage1.
While the cause of AD remains unknown, several risk factors have been identified that may provide insight 
into the fundamentals of AD pathogenesis. Among them, aging is by far the most important risk factor, but type-2 
diabetes mellitus (T2DM) is also a known risk factor for AD. Compelling evidence supports the notion that insu-
lin deficiency and insulin resistance are involved in AD-type neurodegeneration; (1) increased risk of developing 
mild cognitive impairment (MCI), dementia, or AD in individuals with T2DM2,3 (2) progressive brain insulin 
resistance, insulin deficiency in AD4–7; (3) cognitive impairment in experimental animal models of T2DM8 (4) 
1the Microsoft Research, University of trento centre for computational Systems Biology (cOSBi), Rovereto, 
italy. 2Life Sciences Research Unit, University of Luxembourg, Esch-sur-Alzette, Luxembourg. 3Department of 
Mathematics, University of trento, Povo, trento, italy. 4Department of Medical and Surgical Science, Alma Mater 
Studiorum University of Bologna, Bologna, italy. 5Department of neurobiology, care Sciences and Society, Division 
of neurogeriatrics, Karolinska institutet, Stockholm, Sweden. 6Department of Pharmacy and Biotechnology, Alma 
Mater Studiorum University of Bologna, Bologna, italy. 7Aptuit, an Evotec company, Drug Design and Discovery, 
Verona, italy. 8Present address: Aptuit an Evotec company Drug Design and Discovery, Verona, Italy. 9Present 
address: Megeno S.A.6A, avenue des Hauts-FourneauxL-4362 Esch-sur-Alzette, Esch-sur-Alzette, Luxembourg. 
correspondence and requests for materials should be addressed to L.c. (email: Laura.caberlotto@gmail.com)
Received: 19 October 2018
Accepted: 29 January 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:3965  | https://doi.org/10.1038/s41598-019-39828-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
improved cognitive performance in experimental models and humans with AD or MCI after treatment with insu-
lin sensitizer agents or intranasal insulin9–16 (5) shared molecular, biochemical, and mechanistic abnormalities in 
T2DM and AD2,17,18. Based on the concept that AD may represent a brain-specific form of diabetes mellitus, the 
term “type-3 diabetes” indicating AD was coined4,19.
Cross-disease therapeutic potential of these major chronic diseases of aging is already showing promise 
as intranasal insulin improves cognitive performances in patients with mild cognitive impairment and AD20. 
Moreover, new generation anti-diabetic incretin drugs show efficacy in AD animal models21,22, and are presently 
being evaluated in clinical trials in patients, as well as thiazolidinedione antidiabetic agents23.
Systems biology has been paving the way to the exploration of complex associations of diseases and, thus, to 
the inference of the pathogenic mechanism of a particular disease by considering disease-related components 
in a large-scale network. Thus, in the present study we set to determine the similarities and differences in the 
molecular mechanistic networks underlying brain T2DM pathophysiology in AD and in neurologically normal 
subjects. A novel approach to the analysis of existing transcriptional data-sets of T2DM and AD patient cerebral 
cortex material was used, with a major application to human brain networks (Fig. 1). This integration of knowl-
edge highlighted a central role for the autophagy pathway in the mechanisms underlying the commonalities in 
AD and T2DM, which was further analyzed in animal models of disease. We focus our investigation initially on 
human diseased subjects considering the limitation of animal models of CNS-related diseases in representing all 
aspects of a complex multifactorial disease, but we were also able to confirm and investigate further the molecular 
mechanism found to be altered in two models that represent different aspects of the genetic of AD.
Figure 1. Schematic representation of experimental design. The transcriptional signature associated to AD 
or T2DM was extracted from transcriptomic data of post-mortem cerebral cortices of AD or T2DM affected 
individuals as compared to controls. Network analysis was then performed with the reference protein-protein 
interaction (PPI) network derived from Biogrid data. The functionality analysis of the networks was then 
performed by testing over-represented Gene Ontology biological process terms and pathways. The relevance 
of autophagy, the most significant pathway identified by network analysis, was further validated in two animal 
models of AD.
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These findings contribute to opening new ways to tackle some of the more important challenges to combat 
these disorders.
Results
Network analysis of human transcriptomic data. We extracted the following transcriptomic profiles 
from the GSE36980 dataset: T2DM controls (n = 20), non-T2DM controls (n = 12), T2DM AD (n = 6), and non-
T2DM AD subjects (n = 19). Having obtained four well defined groups representing all combinations of our two 
phenotypes of interest (T2DM and AD), we sought to characterize them transcriptionally in a highly specific way, 
in the sense of identifying genes whose expression changes were most related to a single phenotype. We derived 
the set of fold changes profiles by dividing each original profile by a reference one obtained as the genewise aver-
age across the whole dataset.
We then applied a rank-based signature extraction algorithm that characterizes each sample by the list of 
genes with the most extremes fold changes in the corresponding profile. As part of the algorithm, we measured 
the degree of similarity between each pair of signatures, and we used the resulting similarity matrix to plot a map 
of the samples and their relative similarity (Supplementary Figure 1). We found that it was necessary to perform a 
preliminary feature selection step in order to preferentially steer the algorithm toward brain transcriptional alter-
ations that have some association to T2DM and AD, reducing the influence of other factors such age, sex, tissue 
of origin. We empirically determined that the best results in terms of separation of the groups were obtained by 
filtering genes whose fold changes showed a sufficiently large difference between average T2DM and non-T2DM 
values in either the AD or the non-AD cohort (t-test, p-value < 0.01). Despite having based the selection on 
T2DM status, we noticed that the selected features (N = 483) included a sufficient number of genes differentially 
expressed between AD and non-AD profiles (N = 103 out of 483).
Having identified list of signature genes capable of separating each of the four group from the others to a 
satisfactory degree (Supplementary Figure 1), we proceeded to select two of the groups (T2DM controls and 
non-T2DM AD subjects) for a more detailed analysis. The consensus transcriptional signature for each of these 
two groups was extracted using an algorithm that summarizes the level of popularity of signature genes across 
the signatures of that group.
The resulting T2DM transcriptional signature consisted of 126 genes, while the AD signature was composed 
of 108 genes (Supplementary Table S1).
The transcriptional signatures were computed to be the shortest possible while maintaining high classification 
accuracy. Therefore, to expand the comprehension of the pathophysiological processes underlying the inves-
tigated diseases, we enriched the lists of signature genes by means of a network analysis technique leveraging 
available knowledge on human protein-protein interactions. Following enrichment, the AD network included 
620 genes and 889 interactions, while the T2DM network included 641 genes and 869 interactions. Hence, we 
obtained an overlapping AD/T2DM network formed by 158 genes in common between the AD and T2DM net-
works (Supplementary Table S1). The overlapping AD/T2DM network is highly enriched in genes supporting the 
common neurobiological dysregulations of the two diseases.
Functional annotation analysis. The functionality analysis of the networks was then performed by testing 
over-represented Gene Ontology biological process terms and pathways of the signature, the overlapping genes 
between signatures, AD and T2DM networks separately and overlapping genes between these two networks.
The analysis of the AD network GO biological processes terms revealed a predominant role of Neurotrophin 
and Notch signalling, apoptosis, autophagy and inflammatory pathways (Supplementary Table 1). Similar find-
ings were confirmed by the pathway analysis, with the addition of Wnt, estrogen, prolactin and FoxO signalling 
pathways (Table 1).
The T2DM network was characterized by apoptosis and several metabolic-associated processes including 
lipid, carbohydrate and ketone metabolism, cholesterol homeostasis, and autophagy. Moreover, in the T2DM 
network, signalling pathways such as neurotrophin, Notch and Wnt were enriched and, as for the AD network, 
inflammatory pathways were highlighted (Supplementary Table 1). Pathway analysis was in line with the GO 
terms investigation, with the addition of pathways related to insulin, leptin, prolactin, mTOR, ephrin signalling, 
and circadian rhythmicity (Table 2).
In the overlapping AD/T2DM network, a strong involvement of autophagy was further confirmed (Figs 2 and 3). 
In addition, apoptosis and Notch signalling were strongly involved together with oxidative stress and inflam-
mation functions (Fig. 2, Supplementary Table S1). Functional Pathway enrichment analysis confirmed the GO 
terms findings and indicated a role also for FoxO, Wnt, estrogen, and leptin signalling pathways (Table 3).
The main functional annotation analysis results of the two networks separately and of the overlapping AD/
T2DM network are summarized in Figs 2 and 3, which highlights the central role discovered for the autophagic 
pathway.
Validation in animal models of disease. Network analyses indicated that autophagy could be among 
the biological mechanisms underpinning both AD and T2DM, thus we performed a focused gene expression 
investigation in two animal models of Alzheimer’s disease with the aim of expanding the knowledge of the roles 
played by specific genes belonging to this pathway in the pathophysiology of this neurodegenerative disease. In 
the pre-frontal cortex of 3xTg-AD mice, a differential expression was detected for 11 genes involved in the auto-
phagic pathway (Fig. 4, Table 4). The evidence of dysregulation was particularly strong for Cyclin-Dependent 
Kinase Inhibitor 1B (Cdkn1b) and for Autophagy Related 16-Like 2 (Atg16l2), which both showed much higher 
expression levels in 3xTg-AD mice with respect to wild-type controls (Fig. 4).
In the ApoE4 targeted replacement (TR) mice, 14 genes involved in the autophagic process showed altered 
expression as compared to the ApoE3 mice (Fig. 5, Table 4). Among those, higher insulin gene expression in the 
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ApoE4 genotype is highlighted (Fig. 5). In addition, mice belonging to each genotype were fed for six months 
with a high carbohydrate diet to stress the metabolism or with a normal diet and the alteration in gene expres-
sion was assessed. The results showed an overall modest impact of the high carbohydrate diet. In particular, Fas 
gene expression was up-regulated in the high carbohydrate diet vs. normal diet in the ApoE3 genotype, whereas 
Dram1 was strongly expressed in the high carbohydrate diet vs. normal diet in the ApoE4 genotype.
Discussion
There is an ongoing debate about the role of T2DM in contributing to AD pathogenesis. Epidemiological and bio-
logical evidence strongly suggests the importance of T2DM components in AD pathology4,6, thus in the present 
study we investigated the molecular basis of this comorbidity applying a systems biology approach to transcrip-
tomic data of human post mortem brains of AD or T2DM affected individuals.
AD and T2DM specific networks were built using a two-step workflow consisting in the identification of 
transcriptomic signatures followed by functional analysis based on network analysis. This approach allowed the 
identification of the molecular mechanisms underlying T2DM and AD and the commonalities and differences 
between the two.
AD network pathway enrichment confirmed previous findings supporting a role for inflammation in the 
pathophysiology of the disease. In the onset of inflammatory process the overexpression of specific interleukins 
such as (IL)-1 plays a relevant role producing many reactions in a loop that cause dysfunction and neuronal 
death24. In our AD network, but also in the T2DM network, we found the interleukin 7 receptor (IL7R). This 
interleukin receptor has been mostly known as a key regulator of T lymphocyte development and homeostasis, 
but recently it has been associated also to obesity and insulin resistance25, suggesting that this could possibly 
represent the molecular link between inflammatory pathways and metabolic alterations. Immune response and 
regulation of metabolism are highly integrated processes, dysfunction of which can lead to a cluster of chronic 
metabolic disorders including insulin resistance.
The analysis of the AD/T2DM overlapping network showed that the autophagic pathway is a crucial compo-
nent in the pathophysiology of both diseases. Autophagy is a major catabolic pathway that allows recycling of 
cellular constituents into bioenergetic and biosynthetic materials for maintenance of homeostasis. In particular, 
neuronal autophagy is essential for synaptic plasticity, anti-inflammatory function in glial cells, oligodendrocyte 
development, and myelination process26,27. Indeed, a wealth of recent data indicated that autophagy plays a major 
role in the pathogenesis of AD28,29. These findings are particularly relevant since our open approach was not based 
on a pre-defined hypothesis. Dys-regulations in autophagy-related genes and proteins has been demonstrated 
in animal models of disease and in patients30; moreover, genetic studies reported associations between several 
autophagy genes and AD31. It has been proposed that the molecular mechanism underlying the association is 
based on the function of autophagy as a major pathway for the clearance and degradation of aggregated and toxic 
proteins29,32. Moreover, impaired mitophagy has also been associated to AD; mitophagy is the process by which 
p value q value Pathway Source
6.75E-13 1.40E-11 Ubiquitin mediated proteolysis - Homo sapiens (human) KEGG
5.04E-10 8.57E-09 NOTCH1 Intracellular Domain Regulates Transcription Reactome
2.06E-09 3.24E-08 Adaptive Immune System Reactome
7.35E-08 7.91E-07 Signaling by NOTCH Reactome
2.91E-07 2.95E-06 HDACs deacetylate histones Reactome
3.16E-06 2.58E-05 FoxO signaling pathway - Homo sapiens (human) KEGG
3.20E-05 0.00022031 Macroautophagy Reactome
4.16E-05 0.00027593 Regulation of autophagy - Homo sapiens (human) KEGG
4.57E-05 0.00028679 Oxidative Stress Induced Senescence Reactome
0.0005419 0.00254964 Activation of NF-kappaB in B cells Reactome
0.0006026 0.0027859 Wnt signaling pathway - Homo sapiens (human) KEGG
0.0007463 0.00336957 Notch signaling pathway - Homo sapiens (human) KEGG
0.0009247 0.004095 Neurotrophin signaling pathway - Homo sapiens (human) KEGG
0.0018044 0.00728684 Amyloids Reactome
0.0018537 0.00745715 Cytokine Signaling in Immune system Reactome
0.0022241 0.00861836 Rap1 signalling Reactome
0.002268 0.00872443 Estrogen signaling pathway - Homo sapiens (human) KEGG
0.0029791 0.01113449 Chemokine signaling pathway - Homo sapiens (human) KEGG
0.0032317 0.01194569 Prolactin signaling pathway - Homo sapiens (human) KEGG
0.0050714 0.01686197 Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) Reactome
0.0055406 0.01830646 Signaling by Interleukins Reactome
0.0079904 0.02504608 Intrinsic Pathway for Apoptosis Reactome
0.0088872 0.02728608 Interferon Signaling Reactome
Table 1. Results of the pathway analysis of the AD network. In bold the pathways in common between the AD 
and T2DM networks.
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cells detect and remove damaged mitochondria by an authophagic mechanism. Thus, impaired mitophagy leads 
to reduced cellular energy levels, increased reactive oxygen species, and impaired neuroplasticity33,34. It is likely 
that both autophagic removal of abnormal proteins and mitophagy-dependent elimination of damaged mito-
chondria are needed to prevent the development of AD. Consequently, although many components still need 
to be elucidated, the identification of the autophagic pathway as a fundamental component of AD aetiology is 
indicating a new direction for the discovery of potential targets for therapeutic intervention which could generate 
disease modifying medicines32,35,36, also addressing the transcriptional control of the process32,37. A number of 
links also exist between T2DM and autophagy, since the latter is the main physiological mechanism activated by 
energy restriction and it could have relevance in pancreatic β-cell homeostasis. Available evidence suggests that 
autophagy deficiency in pancreatic β cells could influence the progression from obesity to T2DM and it could 
contribute to insulin resistance in target organs38–40. The principal players include the central function exerted by 
AMPK, which is both a main regulator of energy metabolism and autophagy and a target of antidiabetic agents41; 
the autophagy-regulator mTOR pathway, which is involved in both glucose homeostasis and insulin resistance42; 
mitochondria dysfunction43,44; and the modulation of inflammation and immune cell function45. Among the 
genes highlighted in the network analysis, four were also confirmed in the Alzheimer’s disease animal models: 
ATG3, GABARAPL2 (ATG8), MAP1LC3B, and SQSTM1. As shown in Fig. 5, two of them GABARPL2 (ATG8) 
and MAP1LC3 are strongly involved in vesicle elongation and autophagosome assembly. ATG8 participates in 
cargo recruitment to the autophagosome46. Also SQSTM1 (p62) a multifunctional scaffolding protein commonly 
found in ubiquitinated inclusion bodies47 is a crucial protein in vesicle trafficking and regulation. The scaffolding 
protein p62 recruits autophagic protein substrates to LC3-bound autophagosomal membranes and it is associated 
with neuropathological inclusions in several neurodegenerative disorders, including AD.
SQSTM1 (p62) immunoreactivity is associated with neurofibrillary tangles and is involved in tau degradation 
and it has been shown that it regulates Aβ turnover. In addition SQSTM1 (p62) overexpression decreases Aβ by 
an autophagy-mediated mechanism and it rescues cognitive function and reduces Aβ pathology in APP/PS1 
mice, a widely used animal model of AD48. Thus, it may play an essential role in eliminating senescent or damaged 
proteins and organelles in neurons and in β-cells, thereby protecting these cells from death. Alteration at this stage 
of sequestration of autophagic cargo, which has been shown to be selective49, could predispose the onset of both 
p value q value Pathway Source
3.74E-15 6.64E-13 Thyroid hormone signaling pathway - Homo sapiens (human) KEGG
1.17E-13 1.38E-11 mechanism of gene regulation by peroxisome proliferators via ppara BioCarta
2.79E-11 2.29E-09 FoxO signaling pathway - Homo sapiens (human) KEGG
1.28E-10 8.49E-09 Macroautophagy Reactome
1.44E-10 9.05E-09 NOTCH1 Intracellular Domain Regulates Transcription Reactome
3.31E-09 1.14E-07 Beta-catenin phosphorylation cascade Reactome
4.50E-09 1.41E-07 Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) Reactome
6.66E-09 1.97E-07 Circadian Clock Reactome
1.15E-08 2.98E-07 Signaling by Interleukins Reactome
1.71E-08 4.05E-07 Circadian rhythm - Homo sapiens (human) KEGG
2.04E-08 4.17E-07 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Reactome
2.47E-08 4.77E-07 AMPK signaling pathway - Homo sapiens (human) KEGG
3.91E-08 7.06E-07 IRS-mediated signalling Reactome
5.72E-08 9.46E-07 Insulin receptor signalling cascade Reactome
2.19E-07 2.72E-06 PI3K-Akt signaling pathway - Homo sapiens (human) KEGG
3.70E-07 4.19E-06 Signaling by Wnt Reactome
9.83E-07 9.35E-06 Signaling by NOTCH Reactome
2.77E-06 2.46E-05 Signaling by Leptin Reactome
4.19E-06 3.46E-05 Adipocytokine signaling pathway - Homo sapiens (human) KEGG
4.89E-06 3.88E-05 Fatty acid, triacylglycerol, and ketone body metabolism Reactome
2.94E-05 0.000165458 Sphingolipid signaling pathway - Homo sapiens (human) KEGG
0.000475166 0.001648377 Wnt signaling pathway - Homo sapiens (human) KEGG
0.000531621 0.001820503 mTOR signalling Reactome
0.001563324 0.004637717 Cellular Senescence Reactome
0.001694211 0.004998158 Neurotrophin signaling pathway - Homo sapiens (human) KEGG
0.003142557 0.008559651 EPH-Ephrin signaling Reactome
0.004303806 0.011317415 Interleukin-6 signaling Reactome
0.006542263 0.015980527 Insulin signaling pathway - Homo sapiens (human) KEGG
0.008386082 0.019505104 Prolactin receptor signaling Reactome
Table 2. Results of the pathway analysis of the T2DM network. In blue the pathways in common between the 
AD and T2DM networks.
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diseases. In support of this hypothesis SQSTM1 (p62) and MAP1LC3B are lower in Alzheimer patients carrying 
the ɛ4/ɛ4 genotype, which is one of the strongest predisposing factors in AD50.
The validation of the role of autophagy-related genes in animal AD models confirmed the importance of this 
pathway and suggested that specific genes are especially dysregulated in the disease model groups. Among them, 
Cyclin-Dependent Kinase Inhibitor 1B (Cdkn1b) and Autophagy Related 16-Like 2 (Atg16l2) showed higher 
expression levels in 3xTg-AD mice.
Cdkn1b is a cyclin-dependent kinase inhibitor able to block cell cycle progression into the proliferative stage. 
In addition to this first-discovered function, subsequent data showed that Cdkn1b is involved in other cellular 
processes, including autophagy. In particular, Cdkn1b is required to induce autophagy in nutrient-depleted cells 
Figure 2. Schematic graphs of over-represented Gene Ontology biological process terms in AD/T2DM 
overlapping network. Over-represented GO terms in the AD/T2DM overlapping network. GO terms are 
represented as nodes, and the strongest GO term pair-wise similarities are designated as edges in the graph. 
GO terms are grouped to illustrate the main biological processes characterizing the overlapping AD/T2DM 
networks. Complete lists of GO terms can be found in Supplementary Table 3.
Figure 3. Integration of AD/T2DM overlapping network with human autophagy network (modified from 
Behrends, C., Sowa, M. E., Gygi, S. P. & Harper, J. W. Network organization of the human autophagy system. 
Nature 466, 68–76 (2010)). AD, T2DM and AD/T2DM genes are charted in the functional integration of the 
autophagy interaction network. In blue are shown the genes validated in the two animal models of AD, in red 
the genes found in the AD network, in green the genes located in the T2Dm network and in pink the AD/T2DM 
genes.
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through its stabilization mediated by AMPK-mediated phosphorylation51. Cdkn1b ability to promote autophagy 
by directly increasing autophagy flux with or without nutrient withdrawal was demonstrated by Sun et al.52 in 
differentiated cardiomyocytes, suggesting that the same could happen in other cell types lacking proliferative 
capacity such as neurons. However, previous studies have reported increased expression of cell cycle proteins 
in neurons of AD patients and it has been put forward that neuronal cell cycle re-entry may be involved in AD 
pathology53. The significance of this process in AD pathology is not clear; it has been proposed that cell cycle 
proteins in post-mitotic neurons may contribute to DNA repair and neuroplasticity53. Cdkn1b involvement in 
AD pathology is supported by data showing altered levels in patient-derived lymphoblasts54 and in post-mortem 
studies55, although in opposite directions. Therefore, our results provide further support to the significance of 
Cdkn1b, although our data do not allow drawing definite conclusions about the mechanism of its action.
Atg16l2 is a poorly characterised gene and its function in the autophagic pathway is incompletely understood. 
Atg16-like proteins interact with Atg5 and Atg12 to form a complex, the E3 ligase, which produces LC3 II, a 
required step in the formation of the autophagosome. While it is established that this function can be accom-
plished by Atg16l1, its homologue Atg16l2 is reported to be able to form the complex, but it does not seem to par-
ticipate in autophagosome formation, at least in starvation-induced autophagy56. On the other hand, ATG16L2 
altered expression or genetic polymorphisms have been associated to multiple sclerosis57,58, Crohn disease59,60, 
and systemic lupus erythematosus61, suggesting that this isoform performs a distinctive, critical function in auto-
phagy. Since Atg16l2 can form hetero-oligomers with Atg16l1, it is possible that the presence of Atg16l2 in the 
complex may modulate the efficiency of autophagy or that Atg16l2 may be involved in a specialised type of auto-
phagy58. In agreement with this notion, Li et al.62 discovered that Atg16l2 interacts with IKKα in pancreatic cells, 
acting as an adaptor protein and exerting an essential role in autophagy in these cells. The reported associations 
with autoimmune diseases suggest the possibility that Atg16l2 may also perform a specific function in the regu-
lation of immune responses. In agreement with our data showing increased levels in a model of a neurodegener-
ative disorder, Sittler et al. detected increased ATG16L2 immunoreactivity in brain regions of Machado‐Joseph 
disease patients63.
In conclusion, this study demonstrated that a systems biology approach can be a powerful tool to identify 
common pathophysiological mechanisms underpinning AD and T2DM. The analysis of human brain transcrip-
tomic data by identification of transcriptional signatures followed by network expansion and functional anno-
tation analysis revealed that a central role is played by autophagy. The relevance of the autophagic pathways was 
validated in diseases models, allowing the identification of specific genes bearing a significant contribution to the 
pathway dysregulation.
Methods
Experimental design. A schematic representation of the study workflow is shown in Fig. 1. A systems biol-
ogy workflow was applied to the transcriptomic data of AD and T2DM affected subjects. Gene expression data 
were analysed with a recently developed algorithm for signature-based clustering of expression profiles to devise a 
transcriptional signature able to discriminate individuals belonging to the disease groups from controls. We iden-
tified a transcriptional signature for each of the two diseases, and performed network analysis in order to expand 
the list of signature genes with the help of protein-protein interactions from the literature. The resulting enlarged 
list was characterized through functional annotation in the form of gene ontologies and canonical pathways. 
The AD and T2DM networks and functional annotation results were then compared. The significant role for the 
autophagic pathway discovered by the system biology approach was then validated by transcriptional analysis of 
selected genes in two relevant animal models of AD coupled with a metabolic challenge.
2.93E-09 5.29E-08 Signaling by NOTCH Reactome
3.90E-09 6.69E-08 FoxO signaling pathway - Homo sapiens (human) KEGG
7.18E-09 1.17E-07 Thyroid hormone signaling pathway - Homo sapiens (human) KEGG
1.14E-07 1.53E-06 Macroautophagy Reactome
1.59E-07 2.05E-06 Cellular Senescence Reactome
1.15E-06 1.27E-05 Signaling by Wnt Reactome
7.82E-06 6.79E-05 Regulation of autophagy - Homo sapiens (human) KEGG
4.92E-05 0.000301243 Wnt signaling pathway - Homo sapiens (human) KEGG
6.25E-05 0.000360329 Notch signaling pathway - Homo sapiens (human) KEGG
0.000211397 0.0010285 Estrogen signaling pathway - Homo sapiens (human) KEGG
0.000262185 0.001207105 Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) Reactome
0.000293703 0.001343203 Signaling by Interleukins Reactome
0.000610253 0.002568306 Oxidative Stress Induced Senescence Reactome
0.000693496 0.002848733 Central carbon metabolism in cancer - Homo sapiens (human) KEGG
0.000864821 0.00342929 Neurotrophin signaling pathway - Homo sapiens (human) KEGG
0.000990053 0.003773201 Signalling by NGF Reactome
0.003406249 0.009736195 Innate Immune System Reactome
0.009010442 0.018960624 Signaling by Leptin Reactome
Table 3. Results of the pathway analysis of the AD/T2DM overlapping network.
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Transcriptomic data. The microarray data set was downloaded from the GEO (GSE36980). The original 
dataset contains gene expression profiles of grey matter from post-mortem brains of AD (n = 16) and non-AD 
controls (n = 23) donated for the Hisayama study64. For our study we used the profiles for which information on 
diabetes mellitus status could be derived from the Hokama et al. paper64. The assessment of AD pathology was 
conducted according to the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) guidelines65 
and the Braak stage66. Clinical data related to T2DM or pre-diabetes were collected as described elsewhere67.
Transcriptomic signature identification. The transcriptional signatures have been identified by means 
of a rank-based classification method previously implemented in the web-tool SCUDO68,69. Briefly, an average 
expression profile was computed and then each of the 57 profiles considered in this study was divided by it. A 
preliminary feature selection step was performed, consisting in a pairwise t test (threshold: p-value < 0.01, genes 
selected were all those appearing in at least one of the two lists resulting from the following two comparisons: 
i) T2DM vs controls subjects, and ii) AD vs controls subjects). Then our classification method was applied; the 
method ranks the filtered genes by expressions level separately for each sample, and then it produces a set of 
subject-specific signatures, where each signature is the list of the first n1 and the last n2 genes in the ranking (n1 
and n2 have the same value for all subjects and are parameters of the method). An all-to-all signature compar-
ison was then carried out using a distance metric based on an enrichment score, resulting in a distance matrix 
that systematically quantifies the degree of similarity between each pair of subjects. The kth percentile of values 
from the distance matrix was then used to build a map of individuals. The map is in the form of a graph where 
the nodes correspond to signatures/subjects and the length of a connecting edge encodes the level of similarity 
between the connected nodes (short edge = high similarity; no edge = negligible similarity). Finally, a consensus 
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Figure 4. Altered mRNA expression levels autophagy-related genes in the pre-frontal cortex of 3xTg-AD 
(PS1tm1Mpm, human APPswe and TauP301L) homozygus mice with respect to wild-type mice. (A) Map1lc3b; 
(B) Sqstm1; (C) Cdkn1b; (D) Atg16l2; (E) Bcl2; (F) Cxcr4; (G) Bnip3; (H) Eif4g1; (I) Ifng; (J) Casp3; (K) Fas. 
***p < 0.001; **p < 0.01; *p < 0.05.
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gene signature was extracted for each group of subjects, which collected all the genes included in at least one 
subject-specific signature for that group. The SCUDO method was used to perform a 4-way classification (four 
groups: T2DM controls, non-T2DM controls, T2DM AD, and non-T2DM AD subjects) with the following 
parameter values: n1 = 100, n2 = 100, k = 10 i.e. bottom 10% of distances was used to generate the graph. Only 
two groups were further studied (T2DM controls and non-T2DM AD subjects), and their consensus signatures 
extracted for further analysis. The consensus signatures for the T2DM and the AD groups included 200 probe 
names each, which produced two lists of 126 and 108 genes (T2DM and AD, respectively) after the probe name to 
gene symbol translation. The translation was performed manually using the annotation table for the Affymetrix 
Human Gene 1.0 ST Array platform downloaded from GEO.
Network enrichment. The networks of AD and T2DM were extracted from the Biogrid Database70 using 
the AD or T2DM disease signatures as seed genes and protein-protein interactions for Homo Sapiens. BioGRID 
is one of the most comprehensive protein interaction databases, containing more than 1,400,000 interactions 
curated from both high-throughput datasets and individual focused studies. From the raw data from BioGrid, 
we considered only non-redundant human interactions. Each unique combination of interactors, protein A and 
protein B, are counted as a single interaction, regardless of directionality, experimental system and publication. 
The genetic inferred interactions were filtered out to remain only physical interactions. We extracted direct 1-step 
interactions of the AD and T2DM genes to construct two corresponding networks, AD network and T2DM net-
work. The network of AD consists of 620 genes and 889 interactions and the network of T2DM contains 599 genes 
and 869 interactions. Both of two networks are not so dense, but rather centralized with some big hub of proteins.
Functional annotation analysis. The gene lists obtained from network enrichment analysis were used 
to extract the most representative GO biological process terms. For identifying and visualizing enriched GO 
terms, we used GOrilla and REVIGO tools71,72. Hypergeometric distribution was applied to test GO term enrich-
ment, and an adjusted p-value (FDR) threshold of 0.05 was selected. Pathway analysis was performed using 
ConsensusPathDB73.
Animals. 3xTg-AD (PS1tm1Mpm, human APPswe and TauP301L) homozygous mice74 and the respective 
C57-derived wild type animals were kindly provided by prof A. Genazzani, University of Eastern Piedmont 
“Amedeo Avogadro”, Italy. Forty-eight weeks old mice of mixed gender were investigated (n = 6/group). The mice 
were housed in groups of 4–6 in ventilated cages (Tecniplast, Italia) with lights on from 7.00 am to 7.00 pm, 
22 ± 2◦C temperature and 65% humidity with water and food ad libitum.
hApoE TR mice expressing human apoE3 and apoE4 under the control of the murine apoE regulatory 
sequences and on a C57BL/6 J background, were purchased from Taconic Farms (USA). Colonies of hApoE3 
(B6.129P2-Apoetm2(APOE*3)Mae N8) and hApoE4 (B6.129P2-Apoetm3(APOE*4)Mae N8) TR mice were 
maintained by homozygous breeding75. The pups were weaned at 3 weeks of age and fed for 6 months with either 
Gene symbol In AD or T2DM network 3xTG vs. wild type ApoE3 vs. ApoE4
ATG3 AD +
GABARAPL2 AD/T2DM +
MAP1LC3B AD/T2DM + +
SQSTM1 AD/T2DM +
Cdkn1b ++
Atg16l2 ++
Bcl2 +
Cxcr4 +
Bnip3 +
Eif4g1 +
Ifng + +
Casp3 +
Fas +
Tnf +
Ins2 ++
Gaa +
Ctss +
Dram1 +
Atg7 +
B2m +
Rps6kb1 +
Ctsb +
Ctsd +
Table 4. Summary table of the gene expression results in the prefrontal cortex of two AD animal models in 
comparison with AD and T2DM networks. +  = p-value ≤ 0.05; +  + corrected p-value ≤ 0.05.
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normal diet (ND) (Mucedola s.r.l., Milano, Italy) or high carbohydrate diet (HCD) containing 70% carbohydrates 
(Mucedola s.r.l.). Adult male mice were selected for the study (n = 6/group).
All experiments were carried out in accordance with Directive 86/609/EEC and approved by the Animal 
Welfare Committee at the University of Bologna (PROT. n. 15-IX/9). Care was taken to minimize the number of 
experimental animals and to take measures to limit their suffering.
RNA extraction and retrotranscription. Mice were sacrificed by cervical dislocation under gaseous anes-
thesia (5% isoflurane in 1 L/min oxygen/nitrous oxide), pre-frontal cortices were dissected and stored at −80 °C. 
Total RNA was extracted by using the Aurum Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad, Hercules, USA) 
following manufacturer’s instructions. RNA was quantified by UV spectrophotometry in a NanoDrop 2000c 
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Figure 5. Altered mRNA expression levels autophagy-related genes in the pre-frontal cortex of hApoE TR mice 
expressing human ApoE3 or ApoE4 fed with either normal diet (ND) or high carbohydrate diet (HC). (A) Atg3; 
(B) Gabarapl2; (C) Map1lc3b (D) Ifng; (E) Tnf; (F) Ins2; (G) Gaa; (H) Ctss; (I) Dram1; (J) Atg7; (K) B2m; (L) 
Rps6kb1; (M) Ctsb; (N) Ctsd. ***p < 0.001;**p < 0.05; *p < 0.05.
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UV-Vis Spectrophotometer (ThermoFisher Scientific); RNA purity was confirmed by a ratio value OD260/
OD280 ≥ 2. RNA integrity was verified by 1% agarose electrophoresis. cDNA was synthesized by using the iScript 
Advanced cDNA synthesis Kit (Bio-Rad) following manufacturer’s instructions.
Quantitative PCR. Quantitative real-time PCR reactions by Sybr Green technology were performed in a 
CFX Real-Time PCR System (Bio-Rad) with 50 ng cDNA and Sso Advanced Universal SYBR Green Supermix 
in Autophagy (SAB Target List) H96 plates (Bio-Rad, cat # 10034108) containing primers for the following 
genes: Actin, Atg3, Atg9b, Bid1, Ctsd, Esr1, Hdac1, Ins2, Nfkb1, Rb1, Tnf, GAPDH, Atg4a, B2m, Bnip3, Ctss, 
Fadd, Hdac6, Irgm1, Npc1, Rgs19, Tnfsf10, Hprt, Ambra1, Atg4b, Bad, casp3, Cxcr4, fas, Hgs, Lamp1, Pik3c3, 
Rps6kb1, Trp53, App, Atg4c, Bak1, Casp8, Dapk1, Gaa, Hsp90aa1, Map1lc3a, Pik3cg, Snca, Ulk1, Atg1, Atg4d, 
Bax, Cdkn1b, Dram1, Gabarap, Hsp90ab1, Map1lc3b, Pik3r4, Sqstm1, Ulk2, Atg12, Atg5, Bcl2, Cdkn2a, Dram2, 
Gabarapl1, Htt, Mapk14, Prkaa1, Tgfb1, Uvrag, Atg16l1, Atg7, Bcl2l1, Cln3, Eif2ak3, Gabarapl2, Ifng, Mapk8, 
Pten, Tgm2, Wipi1, Atg16l2, Atg9a, Becn1, Ctsb, Eif4g1, Gusb, Igf1, Mtor, Rab24, Tmem74, Tbp. To provide 
quantification, a threshold cycle (Ct) number was defined in the early logarithmic phase of the amplification 
plot and the relative expression of gene transcripts was calculated by the Delta-Delta Ct (DDCt) method and 
converted to relative expression ratio (2-DDCt) for statistical analysis76. All data were normalized to the geometric 
average of the endogenous reference genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Actin (Act), 
and TATA box binding protein (Tbp) expression77. A dissociation curve was built in the 60–95 °C range to eval-
uate amplification product specificity.
Statistical analysis of real-time PCR data. The quantitative real-time PCR data was processed in R using 
the RankProd package78. The RP function from the package was used with its default values with n = 10000 per-
mutations for computing the empirical distributions. RankProduct is a rank-based method capable of identifying 
differentially expressed genes with high sensitivity even in the case of a modest number of profiles. Moreover, 
being based on ranks the method makes no assumptions on the distribution of expression values, and it is robust 
to real-time PCR normalization errors.
Data Availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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